ClinicalTrials.gg
WithdrawnNCT07492888Updated May 8, 2026

Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

A Phase 2 interventional study of Nogapendekin Alfa-Inbakicept (NAI) and Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) in Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum and Sepsis, sponsored by ImmunityBio, Inc.. Withdrawn. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by ImmunityBio, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
New protocol developed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 105 Years
Sex
All
01

Study summary

This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired pneumonia (CAP) (with or without sepsis/ARDS) recover. The study will give NAI by subcutaneous injection (Days 1 and 10) and one IV dose of iNKT cells (Day 3), then follow participants for 90 days.

Read the detailed description

Phase 2, single-arm study in up to 20 critically ill adults with severe community-acquired pneumonia (CAP) (with or without sepsis/ARDS) and lymphopenia (ALC \<1,500/µL). The study evaluates the safety, tolerability, and preliminary efficacy of combining an IL-15 superagonist (nogapendekin alfa-inbakicept, NAI) with an allogeneic invariant natural killer T cell product (iNKT cells) added to standard ICU care.

Key elements

Population: Adults (≥18) admitted to ICU for severe CAP within 72 hours, meeting IDSA/ATS severe CAP criteria (≥1 major or ≥3 minor) and on antibiotics.

Planned enrollment: up to 20 participants (≈40 screened).

Intervention schedule:

Day 1: NAI subcutaneous (≤50 kg → 15 µg/kg; >50 kg → fixed 1 mg). Day 3: Single IV infusion of iNKT cells (1 × 10\^9 cells). Day 10: Second NAI subcutaneous dose (same dosing as Day 1). Concomitant care: all participants receive guideline-based standard of care for CAP/sepsis/ARDS (antibiotics, organ support, lung-protective ventilation, vasopressors, low-dose steroids as indicated, etc.).

Safety oversight: continuous ICU monitoring; Sponsor Drug Safety review of SAEs; Safety Review Committee (SRC) reviews safety after first 5 participants and oversees stopping rules. Predefined toxicity rules and management algorithms for infusion reactions, CRS, and ICANS are specified.

Primary endpoints: safety/tolerability (TEAEs, SAEs, grade ≥3 AEs) and 28-day all-cause mortality.

Secondary endpoints: absolute lymphocyte count recovery, ventilator-free days, ICU-free days, antibiotic-free days, days free from organ support, time to ICU/hospital discharge, incidence of secondary infections through Day 28, and 90-day mortality.

Exploratory endpoints: serum cytokines, NK and T-cell expansion and activation/exhaustion markers, monocyte HLA-DR, quantification and persistence of donor iNKT cells (Days 1, 7, 14, 28).

Duration per participant: treatment up to 10 days; follow-up to 90 days after first dose.

Stopping/discontinuation: specified criteria for permanent discontinuation (e.g., drug-related Grade ≥3 organ toxicity, Grade ≥3 CRS/ICANS, intolerable infusion reactions), SRC stopping rules (including treatment-related death or clustered severe toxicities).

Objective: determine whether the NAI + iNKT combination can be given safely in this population and provide signals of reduced 28-day mortality and immune recovery (reversal of lymphopenia) to justify further study.

Sites will collect clinical outcomes, safety data, laboratory panels (CBC/CMP/coagulation), and samples for immune monitoring per protocol schedule.

02

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Severe Community-Acquired Pneum
  • Sepsis
  • Lymphopenia / Immunoparalysis in Critically Ill Adults

Keywords

  • nogapendekin alfa-inbakicept
  • NAI
  • ANKTIVA
  • iNKT cells
  • AgenT-797
  • IL-15 superagonist
  • cell therapy
  • immunotherapy
  • community-acquired pneumonia
  • CAP
  • sepsis
  • sepsis shock
  • acute respiratory distress syndrome
  • ARDS
  • lymphopenia
  • immunoparalysis
  • intensive care unit
  • ICU
  • critical care
  • ventilator-free days
  • immune monitoring
03

In context

Respiratory Distress Syndrome

1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Critically ill adult requiring ICU admission due to severe community acquired pneumonia (CAP), defined by ≥1 major criterion or ≥3 minor criteria (IDSA/ATS):

    • Major: respiratory failure requiring mechanical ventilation OR septic shock requiring vasopressors.
    • Minor: tachypnea (RR ≥ 30), PaO2/FiO2 ≤ 200, multilobar infiltrates, new confusion/disorientation, BUN ≥ 20 mg/dL, count \< 100,000/µL, core temperature \< 36.0°C, hypotension requiring aggressive fluid resuscitation.
  3. Hospital admission with diagnosis of CAP within 72 hours.
  4. Lymphopenia: absolute lymphocyte count (ALC) \< 1,500/µL (not secondary to chemotherapy).
  5. Receiving antibiotics for CAP (at least one dose since ICU admission).
  6. obtainable from participant or legally authorized representative.

Exclusion criteria

Exclusion Criteria-

  1. Hematologic (e.g., active leukemia or lymphoma not in remission).
  2. Post CAR T therapy or hematopoietic cell transplant for ALL, NHL, or multiple myeloma \< 3 months prior to enrollment.
  3. Current diagnosis of cytokine release syndrome.
  4. Receiving colony stimulating factors (e.g., G CSF).
  5. Clinical history or imaging suggesting aspiration of gastric contents.
  6. Advanced dementia or prolonged bedridden status.
  7. Pregnancy or breastfeeding.
  8. High dose therapy at baseline (e.g., > 0.5 mg/kg prednisone or equivalent). (Low dose for septic shock/ARDS per SOC permitted.)
  9. Uncontrolled or inflammatory disease requiring immunosuppressive therapies.
  10. \< 24-48 hours or moribund condition despite care (investigator judgment).
  11. Active uncontrolled bleeding or intracerebral hemorrhage.
  12. Known to ingredients used in the cell product formulation (e.g., DMSO).
  13. Treated by antibiotics for the current respiratory infection for more than seven days at time of hospitalization (unless culture/sensitivity indicates resistant organism to administered antibiotics).
  14. Known active viral hepatitis A, B, or C.
  15. Investigator judgment that participation is not in the participant's best interest or participant is unsuitable for enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NAI Plus iNKT Cells With Standard of Care

    Single-arm treatment: all participants receive nogapendekin alfa-inbakicept (NAI) plus a single infusion of allogeneic iNKT cells in addition to guideline-based standard of care. NAI SC on Day 1 and Day 10 (≤50 kg: 15 µg/kg; \>50 kg: fixed 1 mg). iNKT cells IV single dose on Day 3 (1 × 10\^9 cells). Standard ICU care (antibiotics, ventilation/organ support, vasopressors, low-dose steroids as indicated) provided per site. Continuous safety monitoring with SRC review after first 5 participants.

    Drug: Nogapendekin Alfa-Inbakicept (NAI) · Drug: Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)

Interventions

  • Nogapendekin alfa-inbakicept (NAI) - a recombinant IL-15 superagonist complex (IL-15N72D:IL-15RαSu/IgG1 Fc) administered subcutaneously (Day 1 and Day 10; weight-based 15 µg/kg if ≤50 kg or fixed 1 mg if \>50 kg) to stimulate NK and CD8+ T-cell proliferation and function.

    Also known as: Anktiva, N-803, ALT-803

  • Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - cryopreserved, GMP-manufactured off-the-shelf donor iNKT cell product administered as a single intravenous infusion (1 × 10\^9 cells on Day 3) intended to provide immediate effector function and immunomodulation; cell product thawed and infused per cell-therapy procedures with premedication as indicated.

06

What researchers measure

Primary outcomes

  1. 28-day all-cause mortality

    Proportion of participants who die from any cause within 28 days of first study drug administration.

    Time frame: Day 28 (28 days after first dose)

  2. Treatment Emergent Adverse Events (TEAEs)

    Any new or worsening medical event beginning after the first dose through 30 days post-last dose, collected to characterize overall tolerability.

    Time frame: From first study treatment to 30 days after the participant's last study dose.

  3. Severe Adverse Events (SAEs)

    Events meeting regulatory seriousness criteria (death, life-threatening, hospitalization, disability, congenital anomaly or other medically important events) reported to evaluate major safety risks.

    Time frame: From first study treatment to 30 days after the participant's last study dose (SAEs related to study product reported regardless of last dose date).

  4. Grade ≥3 TEAEs

    Adverse events of CTCAE severity grade 3 or higher that emerge after first dose, used to quantify severe toxicity burden.

    Time frame: From first study treatment to 30 days after the participant's last study dose.

  5. Safety laboratory tests

    Routine clinical labs (CBC, chemistry, coagulation, etc.) collected serially to detect clinically meaningful laboratory abnormalities attributable to treatment.

    Time frame: From baseline (pre-dose) through 30 days after the participant's last study dose.

  6. Temperature

    Serial core body temperature measured in degrees Celsius. Report baseline, maximum post-dose within 24 hours, and incidence of fever \>39.0°C.

    Time frame: Baseline (pre-dose) through End of ICU stay; intensified monitoring for 24 hours after iNKT infusion (vitals every ≥4 hours; continuous telemetry as indicated).

  7. Heart rate

    Serial heart rate (bpm). Report baseline, peak within 24 hours post-infusion, and incidence of new clinically significant tachycardia (\>120 bpm) requiring intervention.

    Time frame: Baseline (pre-dose); maximum post-dose within 24 hours after iNKT infusion (intensified monitoring during this 24-hour window); overall reporting through End of ICU stay (up to 28 days).

  8. Blood pressure

    Serial systolic/diastolic blood pressure (mmHg). Report baseline, nadir within 24 hours post-infusion, and incidence of new hypotension (MAP \<65 mmHg or need for new/increased vasopressor) temporally related to infusion.

    Time frame: Baseline (pre-dose); maximum post-dose within 24 hours after iNKT infusion (intensified monitoring during this 24-hour window); overall reporting through End of ICU stay (up to 28 days).

  9. Respiratory rate

    Serial RR (breaths/min). Report baseline, worst value within 24 hours post-infusion, and incidence of clinically significant tachypnea (RR ≥30) or new respiratory deterioration requiring escalation.

    Time frame: Baseline (pre-dose); maximum post-dose within 24 hours after iNKT infusion (intensified monitoring during this 24-hour window); overall reporting through End of ICU stay (up to 28 days).

  10. Oxygen saturation

    Serial peripheral oxygen saturation (%). Report baseline, nadir within 24 hours post-infusion, and incidence of new hypoxemia (SpO2 \<90% on prior baseline support or increase in FiO2/ventilatory support).

    Time frame: Baseline through End of ICU stay; intensified monitoring for 24 hours after iNKT infusion.

Secondary outcomes

  1. Absolute Lymphocyte Count (ALC)

    Peripheral ALC measured over time to evaluate reversal of lymphopenia and quantitative immune recovery after treatment.

    Time frame: Assessed at baseline and summarized at Days 7, 14, 21, and 28 after first dose.

  2. Ventilator-free days (VFD) through Day 28

    From first study treatment through Day 28 after first dose.

    Time frame: Number of days within the 28-day window the participant is alive and free from mechanical ventilation, with death or ventilator dependence to Day 28 scored as zero.

  3. ICU-free days through Day 28

    Number of days within 28 days the participant is alive and not in ICU, reflecting time free from intensive care support.

    Time frame: From first study treatment through Day 28 after first dose.

  4. Antibiotic-free days through Day 28

    Number of days within 28 days the participant is alive and not receiving systemic antibiotics for respiratory infection, as a proxy for infection control and clinical recovery.

    Time frame: From first study treatment through Day 28 after first dose.

  5. Days alive and free of other organ support through Day 28

    Count of days within 28 days the participant is alive and not requiring non-respiratory organ supports (eg, vasopressors, renal replacement therapy), reflecting multi-organ recovery.

    Time frame: From first study treatment through Day 28 after first dose.

  6. Time to ICU discharge

    Interval from first dose to date/time participant leaves ICU, used to assess speed of clinical improvement sufficient for lower-level care.

    Time frame: From first study treatment (Day 1) through Day 28 - time to ICU discharge will be reported as days from first dose to date/time of ICU discharge; participants not discharged by Day 28 will be censored at Day 28.

  7. Time to hospital discharge

    From first study treatment until hospital discharge (if occurs).

    Time frame: From first study treatment (Day 1) through Day 28 - time to hospital discharge will be reported as days from first dose to date of hospital discharge; participants not discharged by Day 28 will be censored at Day 28.

  8. Number of secondary infections through Day 28

    Incidence and timing of new clinically documented infections (eg, ventilator-associated pneumonia, bloodstream infection) occurring within 28 days, to evaluate infection risk post-treatment.

    Time frame: From first study treatment through Day 28 after first dose.

  9. Number of secondary infections through participant follow-up

    From first study treatment through 90 days after first dose.

    Time frame: Incidence of new clinically documented infections up to 90 days to capture later-onset infectious complications.

  10. 90-day all-cause mortality

    Death from any cause occurring within 90 days of first treatment to evaluate longer-term survival.

    Time frame: From first study treatment to Day 90 after first dose.

Other outcomes

  1. Serum cytokines

    Serial measurement of inflammatory and regulatory cytokines (eg, IL-6, IL-10, IFN-γ, IL-15) to characterize immune activation, resolution, or dysregulation in response to therapy.

    Time frame: Baseline and at Days 1, 7, 14, and 28 after first dose (or last available in-person visit).

  2. NK cell expansion / T-cell activation-exhaustion markers / other immunologic parameters

    Flow-cytometry and related assays quantifying NK and T-cell counts/phenotype (eg, Ki-67, PD-1) to assess cellular immune activation, proliferation, and exhaustion status post-treatment.

    Time frame: Baseline and Days 1, 7, 14, and 28 after first dose.

  3. Percentage normalizing monocyte HLA-DR by Day 7 and Day 14 and change in HLA-DR expression

    Proportion of participants achieving restoration of monocyte HLA-DR expression (a biomarker of innate immune competence) and magnitude of change from baseline.

    Time frame: Assessed at Days 7 and 14 after first dose.

  4. Quantification of circulating iNKT cells (peak count) and persistence

    Peak peripheral donor iNKT cell counts and duration of detectable donor cells to assess in vivo engraftment/ persistence of the infused product.

    Time frame: Measured at baseline and at Days 7, 14, and 28 after first dose.

  5. Increase in NK cell count by Day 14

    Change in NK cell absolute count at Day 14 versus baseline to evaluate early innate immune expansion attributable to NAI.

    Time frame: From baseline to Day 14 after first dose.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Nov 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 25, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Nov 15, 2026
CompletionEst.
Jan 15, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492888
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797

Start the discussion